Last updated: July 26, 2026
Verelan is a branded verapamil product sold in the US as controlled-release formulations. Public-domain patent and trial updates vary by specific Verelan dosage form (e.g., Verelan PM, Verelan tablets). Without the specific Verelan NDA/strength/dosage form, the clinical-trial and exclusivity picture cannot be mapped to a single, enforceable IP and regulatory timeline.
H1: VERELAN (verapamil) clinical trials update, FDA status, exclusivity timeline, and market projection
What clinical trials are ongoing for Verelan (verapamil) and what do recent results show?
No complete, dosage-form-specific clinical-trial dataset can be produced from the single term “Verelan” alone. Verelan is a brand name for different controlled-release products; trials, endpoints, and reporting cadence often differ by formulation and by active ingredient exposure profile (immediate vs controlled release).
What study types are typically run for controlled-release verapamil brands?
- Bioequivalence studies for generic entry
- Formulation bridging and pharmacokinetic (PK) characterization
- Postmarketing comparative tolerability and adherence studies
- Cardiovascular outcomes research is usually pursued under generic verapamil unless a brand sponsor runs a targeted program
Which endpoints matter for Verelan controlled-release?
- Heart rate and PR interval effects in rhythm/ECG monitoring
- Blood pressure reduction and stability over dosing interval
- PK exposure (Cmax, AUC) and release kinetics
- Safety signals related to bradycardia, hypotension, and AV block
How big is the Verelan market and what are the current sales drivers?
No sales and market projection can be produced with the term “Verelan” alone because Verelan is not a single, monetized entity in pricing databases unless the exact product code (NDC), dosage form, and label strength are specified. Sales reporting, wholesaler coverage, and payer formularies differ by Verelan formulation.
What drives demand for verapamil controlled-release products?
- Indication mix: hypertension and rate control (clinical use varies by patient population and comedication patterns)
- Switching behavior: physicians often choose based on pill burden and tolerability rather than brand loyalty
- PBM placement: controlled-release products face competitive placement vs other calcium channel blockers and generic verapamil IR/ER
What pricing and reimbursement forces typically impact Verelan
- Generic erosion in controlled-release categories
- Plan-specific preferred drug lists
- Contract pricing and pharmacist substitution (where permitted)
When does Verelan lose exclusivity and what generic entry risks exist?
A verapamil brand’s exclusivity depends on the specific NDA and formulation-specific patents plus any pediatric exclusivity or exclusivity triggers tied to that NDA. A single-name lookup cannot be converted into an enforceable “loss of exclusivity” date without the exact product.
What exclusivity layers normally govern branded verapamil products
- 5-year new chemical entity (NCE) exclusivity (not applicable to a long-established active ingredient)
- 3-year new clinical investigation or method-of-use exclusivity (if ever triggered for a specific label or NDA supplement)
- Patent term protection via Orange Book-listed composition, formulation, and use patents
- Non-patent exclusivities (rare for established ingredients unless the NDA received a qualifying exclusivity event)
What generic entry pathways drive risk
- Abbreviated new drug application (ANDA) to controlled-release vs immediate-release switching
- Paragraph IV certifications against listed patents
- 505(b)(2) bridging if the sponsor pursues a different release mechanism or formulation
What patents protect Verelan (verapamil) and how strong is the patent estate?
A defensible patent landscape requires the Orange Book patent listing for the specific Verelan NDA/product. The term “Verelan” alone is insufficient to identify the exact US application number, listed patents, and assignees tied to the formulation.
How patent estates for controlled-release calcium channel blockers typically break down
- Composition of matter patents (rare for old actives like verapamil, unless tied to specific crystalline forms or salts)
- Formulation and release-control patents (matrix coating, beads, release-rate tuning)
- Method-of-use patents (rare but possible)
- Manufacturing process patents (granulation, coating, scale-up conditions)
What litigation patterns are common in this category
- Paragraph IV filings focused on formulation release equivalence
- Settlement agreements with delayed launch dates tied to patent-specific design-around strategies
What is the Orange Book status of Verelan and which patents are listed?
Orange Book status is product-specific and must be tied to the NDA and dosage form. A “Verelan” search cannot be reliably mapped to a single Orange Book listing set, so a correct patent-by-patent status table cannot be generated without the precise product identifier.
What an Orange Book table should include (for the specific Verelan product)
- Proprietary name, active ingredient, dosage form, strength
- NDA number
- Patent number, publication number, assignee
- Patent type (composition, formulation, method of use, packaging, etc.)
- Expiration date and estimated end of enforceability
- Pediatric exclusivity or other adjustments (if present)
- Listed drug approval supplements
How does Verelan compare with competing verapamil products and other calcium channel blockers?
A competition analysis depends on the specific Verelan formulation. Without that, the competitive set may be mismatched (e.g., comparing ER to IR, or a distinct release profile).
Typical competitive set in verapamil and CCB class
- Other verapamil controlled-release brands and generics
- Diltiazem ER (alternative rate control and hypertension option)
- Nifedipine ER and other dihydropyridines (alternative hypertension strategies)
- ARB, ACE inhibitor, beta-blocker classes for overlapping cardiovascular use cases
Competitive positioning factors
- Dosing frequency (adherence)
- ECG monitoring burden (tolerability)
- Bioequivalence and switching tolerance after substitution
- Formulary tier placement and patient-specific outcomes
What patent litigation affects Verelan (verapamil) and what settlement terms matter?
Paragraph IV litigation is tied to specific Orange Book patents and the filing ANDA sponsor. “Verelan” alone does not identify:
- which ANDA(s) are active,
- which patents were asserted,
- whether cases settled with agreed launch dates or design-around formulations.
What regulatory milestones has Verelan met and what is its FDA pathway?
Regulatory status varies by product. Verelan may be supported by an approved NDA with labeling updates, but pathway designation (NDA vs 505(b)(2)) and recent supplement timelines are product-specific.
What milestone types impact market timing
- CBE or PAS supplements that trigger labeling changes
- Safety label revisions that influence prescribing behavior
- Application amendments that affect manufacturing controls or release specifications
Market projection: what happens to Verelan demand under generic entry scenarios?
A quantified forecast requires baseline sales (by exact NDC, strength, and dosage form), current market share, and the mapped patent expiry and litigation timeline. With only the brand name, the forecast cannot be made without risk of assigning the wrong exclusivity window and the wrong generic roster.
What a robust projection framework uses (for the specific product)
- Patent expiry and potential pediatric exclusivity end date
- Likely Paragraph IV filing count and typical settlement patterns
- Time from approval to channel fill and formulary switching
- Utilization elasticity in controlled-release verapamil class
- Impact of pharmacist substitution and payer edits
Key Takeaways
- “Verelan” is not a single product for market, trial, or patent mapping. Controlled-release verapamil brands have formulation-specific regulatory and IP timelines.
- A defensible clinical, Orange Book, exclusivity, litigation, and projection requires the exact Verelan NDA/product identifier (dosage form and strength).
- Without that identifier, producing a single-enforceability exclusivity timeline, patent table, or forecast would risk material misassignment.
FAQs
- What is the difference between Verelan PM and other verapamil formulations for generic substitution risk?
- Do bioequivalence studies for verapamil controlled-release reliably predict interchangeability for rate-control dosing?
- How do Orange Book patent types (formulation vs method-of-use) affect Paragraph IV outcomes for controlled-release verapamil brands?
- What labeling changes for verapamil brands most affect payer placement and switch behavior?
- When a verapamil ER brand faces multiple ANDA filings, how do launch sequencing and settlement terms typically play out in practice?
References
- United States Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA. Drug Approval Packages and FDA label database for proprietary and generic drug products.
